Developing Effective Molecule Selection Frameworks: Enhancing Portfolio Strategy and Business Growth

This study aims to develop a strategic molecule selection framework to enhance portfolio strategy and business growth within the Philippine branded generic pharmaceutical industry. Its specific objectives are to identify key strategic, financial, and operational factors influencing portfolio decisions, pinpoint common challenges and missed steps, compare selection processes across different generic companies, evaluate benefits and limitations, and formulate implementation mechanisms with performance metrics for long-term adaptability. Employing a quantitative research design, the study surveyed 300 pharmaceutical and healthcare professionals in Makati and Bonifacio Global City using purposive sampling. Data were gathered through structured questionnaires and analyzed via Kendall’s W agreement analysis, Spearman Rank correlation, and Exploratory Factor Analysis (EFA). The results identified "Strategic Market Alignment" and "Operational Resources" as core factors in molecule selection, while revealing a significant correlation between the perceived difficulty of a portfolio step and the frequency of its omission. Furthermore, multinationals prioritized strategic factors more heavily than local manufacturers, and "Process Constraints" such as internal politics and rigid criteria emerged as major decision-making barriers. The study concludes that a systematic, data-driven framework is essential for mitigating risks and achieving a First-to-Market advantage. The proposed framework incorporates a Learning Loop for post-implementation reviews alongside performance metrics like the Selection Efficiency Ratio and Portfolio Velocity. Future research should explore artificial intelligence in market forecasting and expand the geographical scope beyond central business districts.

Generic medicine selection, Market size and potential, Physicians and patients acceptance, Branded generic competition, generic drug regulation

1. U.S. Department of Health & Human Services (ASPE) 2025, Analysis of New Generic Markets: Effect of Market Entry on Generic Drug Prices. [Google Scholar] [Crossref]

2. Frank, R. G., McGuire, T. G., & Nason, I. (2021). The evolution of supply and demand in markets for generic drugs. The Milbank Quarterly, 99(3), 828–852. https://doi.org/10.1111/1468-0009.12517 [Google Scholar] [Crossref]

3. Kaplan, W., Wirtz, V. J., Mantel-Teeuwisse, A., Stolk, P., Duthey, B., & Laing, R. (2013). Priority medicines for Europe and the world 2013 update. World Health Organization. [Google Scholar] [Crossref]

4. Gupta, R., Dhruva, S. S., Fox, E. R., & Ross, J. S. (2017). The FDA Unapproved Drugs Initiative: An observational study of the consequences for drug prices and shortages in the United States. Journal of Managed Care & Specialty Pharmacy, 23(10), 1066–1076. [Google Scholar] [Crossref]

5. https://doi.org/10.18553/jmcp.2017.23.10.1066 [Google Scholar] [Crossref]

6. Nguyen, E. N. T. A. (2025). Strategies to improve project portfolio management in the pharmaceutical industry [Doctoral dissertation, Walden University]. Walden University ScholarWorks. [Google Scholar] [Crossref]

7. DrugPatentWatch 2024, The Global Generic Drug Market: Trends, Opportunities, and Challenges [Google Scholar] [Crossref]

8. Minyoung Bae (2025) A Five-Year Analysis of Market Share and Sales Growth for Original Drugs after Patent Expiration in Korea. [Google Scholar] [Crossref]

9. Henry Grabowski (2021, Continuing trends in U.S. brand-name and generic drug competition [Google Scholar] [Crossref]

10. Simon van der Schans, et al. (2020). The impact of patent expiry on drug prices: insights from the Dutch market. BMC Health Services Research, 20(1). [Google Scholar] [Crossref]

11. Marcin Lewandowski., et al. (2025). Analysis of the physicians' perception of original and generic drugs in Poland. Arterial Hypertension, 29(5). [Google Scholar] [Crossref]

12. Tomoyuki Takura., et al. (2024). Factors Influencing Drug Prescribing for Patients With Hospitalization History in Circulatory Disease–Patient Severity, Composite Adherence, and Physician-Patient Relationship: Retrospective Cohort Study. JMIR Aging, 7(1), e59234. [Google Scholar] [Crossref]

13. Trond Røed Pettersen, et al. (2022). Perceptions of generic medicines and medication adherence after percutaneous coronary intervention: a prospective multicentre cohort study. BMJ Open, 12(9), e061689. [Google Scholar] [Crossref]

14. Md Sayeed Akhtar , Khalid Orayj (2024). Evaluation of public's knowledge, attitude and experiences towards the generic medications in building healthcare policy. PLOS One, 19(11) [Google Scholar] [Crossref]

15. Neetu Bairagi (2024). Overcoming Barriers to Generic Drug Adoption: Insights from Global Studies. ResearchGate. (Review/Study). [Google Scholar] [Crossref]

16. Shaira Mae A. Vitales. (2025). Consumer Preferences between Branded and Generic Medications: A Comparative Study [Google Scholar] [Crossref]

17. Wong, J. Q., et al. (2014). The Prevalence of Philippine Prescribing, Dispensing, and Use Behavior in Relation to Generic Drugs and their Risk Factors. Philippine Institute for Development Studies (PIDS). [Google Scholar] [Crossref]

18. Yixin (Iris) Wang (2022). Manufacturing and Regulatory Barriers to Generic Drug Competition: A Structural Model Approach. Illinois Experts. [Google Scholar] [Crossref]

19. Apratim P. Mahajan (2025). A Comparative Overview of Generic Drug Regulation in US, Europe, Australia and India. International Journal of Drug Regulatory Affairs, 13(1), 40-48. [Google Scholar] [Crossref]

20. Bhosale, P. P., Kore, P. S., Mutal, M. M., & Bhise, A. S. (2025). Survey on marketing strategies of generic versus branded drugs. Asian Journal of Pharmaceutical Analysis, 15(3), 197–202. https://doi.org/10.52711/2231-5675.2025.00031 [Google Scholar] [Crossref]

21. Amatha Sreedevi. (2025). Exploring the challenges faced by generic version of complex drugs: a scoping review. PMC / NIH [Google Scholar] [Crossref]

22. Carolina Santos et.al (2025). The Impact of Multimarket Competition on Generic Drugs' Regulated Prices. Health Economics. [Google Scholar] [Crossref]

23. Shahmoradi Mostafa et. al 2021, Analyzes the impact of government and regulatory policies (both supply-side and demand-side, like INN prescribing or financial incentives) on generic uptake. This is critical as policy significantly shapes the environment for branded generics. [Google Scholar] [Crossref]

24. Apratim P. Mahajan (2025). A Comparative Overview of Generic Drug Regulation in US, Europe, Australia and India. International Journal of Drug Regulatory Affairs, 13(1), 40-48. [Google Scholar] [Crossref]

• Assessment of the Role of Artificial Intelligence in Repositioning TVET for Economic Development in Nigeria
• Teachers’ Use of Assure Model Instructional Design on Learners’ Problem Solving Efficacy in Secondary Schools in Bungoma County, Kenya
• “E-Booksan Ang Kaalaman”: Development, Validation, and Utilization of Electronic Book in Academic Performance of Grade 9 Students in Social Studies
• Analyzing EFL University Students’ Academic Speaking Skills Through Self-Recorded Video Presentation
• Major Findings of The Study on Total Quality Management in Teachers’ Education Institutions (TEIs) In Assam – An Evaluative Study